Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

PubMed  Google Scholar 

Anand U, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023;10(4):1367–401.

Article  CAS  PubMed  Google Scholar 

Kohn KW, Pommier Y. Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors. Ann N Y Acad Sci. 2000;922:11–26.

Article  CAS  PubMed  Google Scholar 

Moukharskaya, J. and C. Verschraegen, Topoisomerase 1 inhibitors and cancer therapy. Hematol Oncol Clin North Am, 2012. 26(3): p. 507–25, vii.

Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6(10):789–802.

Article  CAS  PubMed  Google Scholar 

Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: current perspectives. Bioorg Med Chem. 2004;12(7):1585–604.

Article  CAS  PubMed  Google Scholar 

Tsuchikama K, et al. Exploring the next generation of antibody–drug conjugates. Nat Rev Clin Oncol. 2024;21(3):203–23.

Article  CAS  PubMed  Google Scholar 

Giugliano F, et al. Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep. 2022;24(7):809–17.

Article  CAS  PubMed  Google Scholar 

Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33–46.

Article  CAS  PubMed  Google Scholar 

Narayan P, et al. FDA approval summary: Fam-Trastuzumab Deruxtecan-Nxki for the treatment of unresectable or metastatic HER2-positive breast cancer. Clin Cancer Res. 2021;27(16):4478–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wahby S, et al. FDA approval summary: accelerated approval of Sacituzumab Govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer. Clin Cancer Res. 2021;27(7):1850–4.

Article  CAS  PubMed  Google Scholar 

Li W, et al. Synthesis and evaluation of camptothecin antibody-drug conjugates. ACS Med Chem Lett. 2019;10(10):1386–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nowak C, et al. Forced degradation of recombinant monoclonal antibodies: a practical guide. MAbs. 2017;9(8):1217–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah DD, et al. Effect of photo-degradation on the structure, stability, aggregation, and function of an IgG1 monoclonal antibody. Int J Pharm. 2018;547(1–2):438–49.

Article  CAS  PubMed  Google Scholar 

Kaiser W, et al. Investigating photodegradation of antibodies governed by the light dosage. Int J Pharm. 2021;604:120723.

Article  CAS  PubMed  Google Scholar 

Mason BD, Schöneich C, Kerwin BA. Effect of pH and light on aggregation and conformation of an IgG1 mAb. Mol Pharm. 2012;9(4):774–90.

Article  CAS  PubMed  Google Scholar 

Kerwin BA, Remmele RL Jr. Protect from light: photodegradation and protein biologics. J Pharm Sci. 2007;96(6):1468–79.

Sreedhara A, et al. Effect of ambient light on IgG1 monoclonal antibodies during drug product processing and development. Eur J Pharm Biopharm. 2016;100:38–46.

Article  CAS  PubMed  Google Scholar 

Cockrell GM, et al. Photoinduced aggregation of a model antibody-drug conjugate. Mol Pharm. 2015;12(6):1784–97.

Article  CAS  PubMed  Google Scholar 

Dodds HM, Craik DJ, Rivory LP. Photodegradation of irinotecan (CPT-11) in aqueous solutions: identification of fluorescent products and influence of solution composition. J Pharm Sci. 1997;86(12):1410–6.

Article  CAS  PubMed  Google Scholar 

Thiess CO, et al. Payload-dependent photostability of antibody-drug conjugates. Eur J Pharm Biopharm. 2025;216:114867.

Article  CAS  PubMed  Google Scholar 

Luo S, et al. Insights into photo degradation and stabilization strategies of antibody–drug conjugates with camptothecin payloads. Pharmaceutics. 2025. https://doi.org/10.3390/pharmaceutics17111397.

Article  PubMed  PubMed Central  Google Scholar 

Beck A, et al. Characterization of therapeutic antibodies and related products. Anal Chem. 2013;85(2):715–36.

Article  CAS  PubMed  Google Scholar 

Huang RY, Chen G. Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends. Drug Discov Today. 2016;21(5):850–5.

Article  CAS  PubMed  Google Scholar 

Liu G-Y, et al. Discovery and characterization of an acid-labile serine-lysine cross-link in antibody high-molecular-weight species using a multipronged mass spectrometry approach. Anal Chem. 2023;95(37):13813–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Y, et al. Investigation of high molecular weight size variant formation in antibody-drug conjugates: microbial transglutaminase-mediated crosslinking. J Pharm Sci. 2023;112(10):2629–36.

Article  CAS  PubMed  Google Scholar 

Xu C-F, et al. Discovery and Characterization of Histidine Oxidation Initiated Cross-links in an IgG1 Monoclonal Antibody. Anal Chem. 2017;89(15):7915–23.

Article  CAS  PubMed  Google Scholar 

Liu M, et al. Discovery and characterization of a photo-oxidative histidine-histidine cross-link in IgG1 antibody utilizing 18O-labeling and mass spectrometry. Anal Chem. 2014;86(10):4940–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan Y, et al. Post-column denaturation-assisted native size-exclusion chromatography-mass spectrometry for rapid and in-depth characterization of high molecular weight variants in therapeutic monoclonal antibodies. J Am Soc Mass Spectrom. 2021;32(12):2885–94.

Article  CAS  PubMed  Google Scholar 

Zhang S, et al. Monitoring polysorbate hydrolysis in therapeutic proteins using an ultrasensitive extraction-free fatty acid quantitation method. Anal Biochem. 2022;637:114472.

Article  CAS  PubMed  Google Scholar 

Zhang S, Xiao H, Li N. The characterization of polysorbate. Curr Protoc. 2022;2(7):e489.

Article  CAS  PubMed  Google Scholar 

Zhang S, et al. Prediction of long-term polysorbate degradation according to short-term degradation kinetics. MAbs. 2023;15(1):2232486.

Article  PubMed  PubMed Central  Google Scholar 

Bechtold-Peters K, et al. CMC regulatory considerations for antibody-drug conjugates. J Pharm Sci. 2023;112(12):2965–80.

Article  CAS  PubMed  Google Scholar 

Song W, et al. Simultaneous analysis of the drug-to-antibody ratio, free-drug-related